Cargando…
Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
OBJECTIVE: To propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on b...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207089/ https://www.ncbi.nlm.nih.gov/pubmed/30498353 http://dx.doi.org/10.2147/TCRM.S175772 |
_version_ | 1783366479733850112 |
---|---|
author | Niccoli, Laura Nannini, Carlotta Blandizzi, Corrado Mantarro, Stefania Mosca, Marta Di Munno, Ombretta Goletti, Delia Benucci, Maurizio Gobbi, Francesca Li Cassarà, Emanuele Kaloudi, Olga Cantini, Fabrizio |
author_facet | Niccoli, Laura Nannini, Carlotta Blandizzi, Corrado Mantarro, Stefania Mosca, Marta Di Munno, Ombretta Goletti, Delia Benucci, Maurizio Gobbi, Francesca Li Cassarà, Emanuele Kaloudi, Olga Cantini, Fabrizio |
author_sort | Niccoli, Laura |
collection | PubMed |
description | OBJECTIVE: To propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on bone mass and sexual sphere, and relationship between RA and periodontal disease (PD). METHODS: An overview of existing evidence was undertaken by an expert panel on behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO). Data were extracted from controlled trials, national registries, national health care databases, post-marketing surveys, and, when required by the paucity of controlled studies, from open-label clinical series. Anti-tumor necrosis factor (anti-TNF) and non-anti-TNF-targeted biologics approved for RA were investigated. RESULTS: ADAb formation is chiefly associated with anti-TNFs, and it is reduced by combination therapy with methotrexate. To date, ADAb titration is not advisable for clinical practice, and, in case of anti-TNF secondary failure, a non-anti-TNF biologic is indicated. LLS is observed in anti-TNF receivers and, in most cases, resolves without anti-TNF withdrawal. A non-anti-TNF biologic is advisable in patients experiencing LLS. Non-anti-TNFs demonstrated a low or absent infection risk and are preferable in patients with comorbidities. Due to their positive effects on bone mass, anti-TNFs are indicated in women at osteoporosis risk, whereas non-anti-TNF have been poorly investigated. The emerging evidence of the relationship between RA and PD and the effects on anti-TNF efficacy should lead clinicians to consider the periodontal status in RA patients. Anti-TNFs may exert a positive effect on fertility and sexuality, and clinicians should explore these aspects in RA patients. CONCLUSION: The optimization of biologic therapies by taking into proper account the above issues would improve patient outcomes. |
format | Online Article Text |
id | pubmed-6207089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62070892018-11-29 Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables Niccoli, Laura Nannini, Carlotta Blandizzi, Corrado Mantarro, Stefania Mosca, Marta Di Munno, Ombretta Goletti, Delia Benucci, Maurizio Gobbi, Francesca Li Cassarà, Emanuele Kaloudi, Olga Cantini, Fabrizio Ther Clin Risk Manag Original Research OBJECTIVE: To propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on bone mass and sexual sphere, and relationship between RA and periodontal disease (PD). METHODS: An overview of existing evidence was undertaken by an expert panel on behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO). Data were extracted from controlled trials, national registries, national health care databases, post-marketing surveys, and, when required by the paucity of controlled studies, from open-label clinical series. Anti-tumor necrosis factor (anti-TNF) and non-anti-TNF-targeted biologics approved for RA were investigated. RESULTS: ADAb formation is chiefly associated with anti-TNFs, and it is reduced by combination therapy with methotrexate. To date, ADAb titration is not advisable for clinical practice, and, in case of anti-TNF secondary failure, a non-anti-TNF biologic is indicated. LLS is observed in anti-TNF receivers and, in most cases, resolves without anti-TNF withdrawal. A non-anti-TNF biologic is advisable in patients experiencing LLS. Non-anti-TNFs demonstrated a low or absent infection risk and are preferable in patients with comorbidities. Due to their positive effects on bone mass, anti-TNFs are indicated in women at osteoporosis risk, whereas non-anti-TNF have been poorly investigated. The emerging evidence of the relationship between RA and PD and the effects on anti-TNF efficacy should lead clinicians to consider the periodontal status in RA patients. Anti-TNFs may exert a positive effect on fertility and sexuality, and clinicians should explore these aspects in RA patients. CONCLUSION: The optimization of biologic therapies by taking into proper account the above issues would improve patient outcomes. Dove Medical Press 2018-10-24 /pmc/articles/PMC6207089/ /pubmed/30498353 http://dx.doi.org/10.2147/TCRM.S175772 Text en © 2018 Niccoli et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Niccoli, Laura Nannini, Carlotta Blandizzi, Corrado Mantarro, Stefania Mosca, Marta Di Munno, Ombretta Goletti, Delia Benucci, Maurizio Gobbi, Francesca Li Cassarà, Emanuele Kaloudi, Olga Cantini, Fabrizio Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables |
title | Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables |
title_full | Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables |
title_fullStr | Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables |
title_full_unstemmed | Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables |
title_short | Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables |
title_sort | personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207089/ https://www.ncbi.nlm.nih.gov/pubmed/30498353 http://dx.doi.org/10.2147/TCRM.S175772 |
work_keys_str_mv | AT niccolilaura personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT nanninicarlotta personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT blandizzicorrado personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT mantarrostefania personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT moscamarta personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT dimunnoombretta personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT golettidelia personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT benuccimaurizio personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT gobbifrancescali personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT cassaraemanuele personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT kaloudiolga personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables AT cantinifabrizio personalizationofbiologictherapyinpatientswithrheumatoidarthritislessfrequentlyaccountedchoicedrivingvariables |